<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34593615</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-3296</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>77</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Thorax</Title>
          <ISOAbbreviation>Thorax</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Epinephrine (adrenaline) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>563</StartPage>
          <EndPage>572</EndPage>
          <MedlinePgn>563-572</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/thoraxjnl-2021-217124</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">International asthma guidelines recommend against epinephrine (adrenaline) administration in acute asthma unless associated with anaphylaxis or angio-oedema. However, administration of intramuscular epinephrine in addition to nebulised selective β<sub>2</sub>-agonist is recommended for acute severe or life-threatening asthma in many prehospital guidelines. We conducted a systematic review to determine the efficacy of epinephrine in comparison to selective β<sub>2</sub>-agonist in acute asthma.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We included peer-reviewed publications of randomised controlled trials (RCTs) that enrolled children or adults in any healthcare setting and compared epinephrine by any route to selective β<sub>2</sub>-agonist by any route for an acute asthma exacerbation. The primary outcome was treatment failure, including hospitalisation, need for intubation or death.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-eight of 1140 studies were included. Overall quality of evidence was low. Seventeen studies contributed data on 1299 participants to the meta-analysis. There was significant statistical heterogeneity, I<sup>2</sup>=56%. The pooled Peto's OR for treatment failure with epinephrine versus selective β<sub>2</sub>-agonist was 0.99 (0.75 to 1.32), p=0.95. There was strong evidence that recruitment age group was associated with different estimates of the odds of treatment failure; with studies recruiting adults-only having lower odds of treatment failure with epinephrine. It was not possible to determine whether epinephrine in addition to selective β<sub>2</sub>-agonist improved outcomes.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The low-quality evidence available suggests that epinephrine and selective β<sub>2</sub>-agonists have similar efficacy in acute asthma. There is a need for high-quality double-blind RCTs to determine whether addition of intramuscular epinephrine to inhaled or nebulised selective β<sub>2</sub>-agonist improves outcome.</AbstractText>
          <AbstractText Label="PROSPERO REGISTRATION NUMBER" NlmCategory="UNASSIGNED">CRD42017079472.</AbstractText>
          <CopyrightInformation>© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Baggott</LastName>
            <ForeName>Christina</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-3581-4472</Identifier>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute of New Zealand, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hardy</LastName>
            <ForeName>Jo Katherine</ForeName>
            <Initials>JK</Initials>
            <Identifier Source="ORCID">0000-0002-3368-095X</Identifier>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute of New Zealand, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sparks</LastName>
            <ForeName>Jenny</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute of New Zealand, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabbagh</LastName>
            <ForeName>Doñah</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute of New Zealand, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beasley</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-0337-406X</Identifier>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute of New Zealand, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Capital and Coast District Health Board, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weatherall</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, University of Otago Wellington, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fingleton</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-9148-196X</Identifier>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute of New Zealand, Wellington, New Zealand james.fingleton@ccdhb.org.nz.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Capital and Coast District Health Board, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medicine, University of Otago Wellington, Wellington, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Thorax</MedlineTA>
        <NlmUniqueID>0417353</NlmUniqueID>
        <ISSNLinking>0040-6376</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7487-88-9</RegistryNumber>
          <NameOfSubstance UI="D008278">Magnesium Sulfate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YKH834O4BH</RegistryNumber>
          <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000318" MajorTopicYN="N">Adrenergic beta-Agonists</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018927" MajorTopicYN="Y">Anti-Asthmatic Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008278" MajorTopicYN="N">Magnesium Sulfate</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">asthma</Keyword>
        <Keyword MajorTopicYN="N">asthma guidelines</Keyword>
        <Keyword MajorTopicYN="N">critical care</Keyword>
        <Keyword MajorTopicYN="N">emergency medicine</Keyword>
        <Keyword MajorTopicYN="N">paediatric asthma</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34593615</ArticleId>
        <ArticleId IdType="doi">10.1136/thoraxjnl-2021-217124</ArticleId>
        <ArticleId IdType="pii">thoraxjnl-2021-217124</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
